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Abstract
Ebola, considered till recently as a rare and endemic disease, has dramatically
transformed into a potentially global humanitarian crisis. The genome of Ebola,
a member of the Filoviridae family, encodes seven proteins. Based on the
recently implemented software (PAGAL) for analyzing the hydrophobicity and
amphipathicity properties of alpha helices (AH) in proteins, we characterize the
helices in the Ebola proteome. We demonstrate that AHs with characteristically
unique features are involved in critical interactions with the host proteins. For
example, the Ebola virus membrane fusion subunit, GP2, from the envelope
glycoprotein ectodomain has an AH with a large hydrophobic moment. The
neutralizing antibody (KZ52) derived from a human survivor of the 1995 Kikwit
outbreak recognizes a protein epitope on this AH, emphasizing the critical
nature of this secondary structure in the virulence of the Ebola virus. Our
method ensures a comprehensive list of such `hotspots'. These helices
probably are or can be the target of molecules designed to inhibit AH mediated
protein-protein interactions. Further, by comparing the AHs in proteins of the
related Marburg viruses, we are able to elicit subtle changes in the proteins that
might render them ineffective to previously successful drugs. Such differences
are difficult to identify by a simple sequence or structural alignment. Thus,
analyzing AHs in the small Ebola proteome can aid rational design aimed at
countering the `largest Ebola epidemic, affecting multiple countries in West
Africa' ( ).http://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/index.html
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            Amendments from Version 2
In the current version, we provide previous research that 
corroborates our hypothesis that helices with characteristically 
unique properties are involved in host protein interactions. 
Specifically, 3FKEA.HELIX2 from VP35, 4U2XA.HELIX7 from VP24 
and 3FKEA.HELIX1 from VP35 are shown to have significance 
in the viral protein interactions. Figure 3d and Table 5 (with a 
corresponding shift in the subsequent table numbering) are 
additional in this version.
See referee reports
REVISED
Introduction
The Ebola virus was first discovered in 19761, and has been since 
known as a rare, but deadly disease2. However, the current out-
break in West African countries (Guinea, Liberia, Nigeria, Sierra 
Leone and Senegal) has rapidly deteriorated into a full blown epi-
demic3, and poses grave humanitarian dangers to these countries4. 
Ebola, along with the Marburg virus, belongs to the Filoviridae 
family5, and causes haemorrhagic fever2 by quickly suppressing 
innate antiviral immune responses to facilitate uncontrolled viral 
replication6.
Interestingly, the genome of the Ebola virus encodes seven proteins7, 
although their extreme ‘plasticity allows multiple functions’8,9. 
Protein structures are formed by well ordered local segments, 
of which the most prevalent are alpha helices (AH) and β sheets. 
AHs are right-handed spiral conformations which have a hydrogen 
bond between the carbonyl oxygen (C=O) of each residue and the 
alpha-amino nitrogen (N-H) of the fourth residue away from the 
N-terminal. AH domains are often the target of peptides designed 
to inhibit viral infections10–12. Recently, we have provided open 
access to software that has reproduced previously described com-
putational methods13 to compute the hydrophobic moment of AHs 
(PAGAL14).
In the current work, we characterize the helices in the Ebola 
proteome using PAGAL, and demonstrate that the helices with 
characteristically unique feature values are involved in critical 
interactions with the host proteins. The PDB database is queried 
for the keyword ‘Ebola’, and the structures obtained are analyzed 
using DSSP15 for identifying AHs. We process all PDB structures, 
and do not filter out redundant structures based on sequence. These 
helices are analyzed using PAGAL, and the results are sorted based 
on three criteria - hydrophobic moment and high proportion of 
positive or negative residues. The helices that are ranked highest in 
these sorting criteria are involved in critical interactions with either 
antibodies or host proteins. For example, the Ebola virus membrane 
fusion subunit, GP2, from the envelope glycoprotein ectodomain 
has an AH with the largest hydrophobic moment in all helices ana-
lyzed16. This helix has part of the epitope recognized by the neutral-
izing antibody (KZ52) derived from a human survivor of the 1995 
Kikwit outbreak, emphasizing the critical nature of this helix in the 
virulence of Ebola17. Another example, obtained by choosing the 
helix with the highest proportion of negatively charged residues, 
is the interaction between the human karyopherin alpha nuclear 
transporters C terminus and the Ebola virus VP24 protein (eVP24)18, 
which suppresses tyrosine-phosphorylated STAT1 nuclear import19. 
These helices probably are, or can be, the target of molecules 
designed to inhibit AH mediated protein-protein interactions20. Our 
method provides a comprehensive list of such targets. Further, each 
protein can be individually queried using PAGAL, and thus identify 
helices that might have a poor global rank, but still be critical in the 
particular proteins context.
Although, Ebola and Marburg viruses are members of the Filoviri-
dae family21, they have different antigenicity of the virion glyco-
protein22. By comparing the AHs in proteins of Marburg and Ebola 
viruses, we are able to elicit subtle changes in the proteins that might 
render them ineffective against previously successful drugs. These 
differences are not apparent from a simple sequence or structural 
alignment. Thus, in the current work, we elucidate a simple method-
ology that can aid rational design of drugs and vaccine, an important 
aspect of the global effort to counter the deadly Ebola epidemic.
Materials and methods
We searched for the keyword ‘Ebola’ in the PDB database (Table 1). 
Subsequently, each protein was split based on the chain id, result-
ing in 146 single chained proteins (See ALPHA.zip in Dataset 1). 
We have not reduced the set based on sequence similarity since 
the proteins might have different conformations based on their lig-
ands. Note, this list might include non-Ebola proteins which might 
have been co-crystallized with the Ebola protein. However, they 
have been put through the same analysis since they might provide 
insights into the Ebola proteins themselves.
These proteins were then analyzed using DSSP15, and resulted in 
758 helices in all (See ALPHA.zip in Dataset 1). These helices 
were then analyzed using PAGAL. The PAGAL algorithm has been 
detailed previously14. Briefly, the Edmundson wheel is computed by 
considering a wheel with centre (0,0), radius 5, first residue coor-
dinate (0,5) and advancing each subsequent residue by 100 degrees 
on the circle, as 3.6 turns of the helix makes one full circle. We 
compute the hydrophobic moment by connecting the center to the 
coordinate of the residue and give it a magnitude obtained from the 
hydrophobic scale (in our case, this scale is obtained from13). These 
vectors are then added to obtain the final hydrophobic moment.
The color coding is as follows: all hydrophobic residues are colored 
red, while hydrophilic residues are colored in blue: dark blue for 
positively charged residues, medium blue for negatively charged 
residues and light blue for amides.
The raw file generated by analyzing all 146 proteins through 
PAGAL is provided as PAGALRAWDATA.txt (Dataset 1), and 
contains the hydrophobic moment, percent of positive charges and 
Table 1. PDB ID of Ebola proteins analyzed.
PDB ID Description
1EBO,2EBO,3VE0,3CSY.. 
2I8B,3V7O 
3FKE,3L25,4LG2,4IBK... 
3VNE,4D9O,4M0Q,4U2X.. 
4QAZ,4QAZ 
1ES6,1H2D,3TCQ,4LDM...
Ebola virus envelope protein 
Minor nucleoprotein VP30 
Polymerase cofactor VP35 
Membrane-associated protein VP24 
Nucleoprotein 
Matrix protein VP40
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the total number of charged residues for every helix. These are then 
sorted based on the charge (negative or positive) or the hydrophobic 
moment. We ignore the helices that have none or a single charged 
residue, and those that are smaller than 10 residues in length. The 
proportion of charged residues is computed based on the total 
number of charged residues, and not the length of the helix.
All protein structures were rendered by PyMol (http://www.pymol.
org/). The sequence alignment was done using ClustalW23. The 
alignment images were generated using Seaview24. Protein struc-
tures have been superimposed using MUSTANG25.
Results and discussion
Dataset 1. PAGAL analysis of Ebola-related alpha helices
http://dx.doi.org/10.5256/f1000research.5573.d37453 
A PDB database search using the keyword ‘Ebola’ generate 
146 single chained proteins, which were analyzed using Define 
Secondary Structure of Proteins, resulting in 758 alpha helices 
(ALPHA.zip). Note, this list might include non-Ebola proteins which 
might have been co-crystallized with the Ebola protein. These 
helices were analyzed using PAGAL (PAGALRAWDATA.txt), which 
details the hydrophobic moment, percent of positive charges and 
the total number of charged residues for every helix.
Helices with large hydrophobic moment
We began by analyzing the helices which have a large hydropho-
bic moment (hydrophobic scale is obtained from13) (Table 2). 
The Edmundson wheel for the helix 1EBOE.HELIX1 from the 
structure of GP2 from the Ebola virus membrane fusion glyco-
protein (PDBid:1EBO)16 is shown in Figure 1a. Figure 1b shows 
the residues comprising these helices (in magenta) in the apo form 
(PDBid:1EBO)16. The neutralizing antibody (KZ52) derived from 
a human survivor of the 1995 Kikwit outbreak (PDBid:3CSY)17 
recognizes an epitope on this AH, emphasizing the critical nature 
of this AH in the virulence of the Ebola virus (Figure 1c,d). The 
antibody most likely inhibits the rearrangement of GP2 segments, 
which abrogates the fusion of the internal loop in the host mem-
brane17. Table 3 shows the residues in the specified helix (residues 
553-597, chain J, PDBid:3CSY) making possible hydrogen bonds 
Table 2. Identifying helices with unique properties. Property 
based on which the sorting is done is either the Hydrophobic moment 
(HM) and the percentage of negative (NEG) or positive residues 
(POS). HM: Hydrophobic moment, RPNR: Ratio of the positive to the 
negative residues, Len: length of the helix, NCH: number of charged 
residues. GP: glycoprotein from Ebola, VP24: Membrane-associated 
protein from Ebola, VP35: Polymerase cofactor.
Property Protein Helix Len HM RPNR NCH
HM GP 
GP
1EBOE.HELIX1 
1EBOE.HELIX0
46 
29
16.2 
11.5
0.5 
0.5
11 
13
NEG VP24 
VP35
4U2XA.HELIX5 
3FKEA.HELIX2
16 
14
4.4 
3.2
0 
0.2
2 
4
POS VP24 
VP35
4U2XA.HELIX7 
3FKEA.HELIX1
19 
15
6.5 
7.8
0.8 
0.8
5 
4
(a)
(b)
(c)
(d)
Figure 1. Helix with large hydrophobic moment in GP2 from the 
Ebola virus membrane fusion glycoprotein. (a) Edmundson wheel 
for 1EBOE.HELIX1. The hydrophobic moment vector is not to scale. 
The color coding is as follows: all hydrophobic residues are colored 
red, while hydrophilic residues are colored in blue: dark blue for 
positively charged residues, medium blue for negatively charged 
residues and light blue for amides. (b) Structure of PDBid:1EBOE, 
1EBOE.HELIX1 is marked in magenta and the leucine zipper is in 
blue. (c) 1EBOE.HELIX1 is disrupted by an antibody derived from 
a human survivor of the 1995 Kikwit outbreak (PDBid:3CSY). (d) 
Gly553/N on 1EBOE.HELIX1 makes a possible hydrogen bond to 
Thr100/OG1 at a distance of 2.7 Å.
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(a) (b)
(c)
Figure 2. Helix 4U2XA.HELIX5 from membrane-associated protein VP24 with a high proportion of acidic residues.  (a) Edmundson 
wheel for 4U2XA.HELIX5. (b) Complex of VP24 (PDBid:4U2XA) and human karyopherin alpha nuclear transporters (KPNA) C terminus 
(PDBid:4U2XD). D124 from VP24 probably has an electrostatic interaction with K481 from KPNA. This interaction is sufficient to interfere with 
the immune response to Ebola infection.
with different residues in the human Fab KZ52 heavy chain (resi-
dues 1-228, chain A, PDBid:3CSY). Among all the interactions, 
only Gly553 is on 1EBOE.HELIX1 (at a distance of 2.7 Å from 
Thr100/OG1), although the others are sequentially proximal. These 
few interactions are sufficient to bind to this helix, rendering the 
virus non-virulent, and leading to human recovery. The importance 
of interfacial hydrophobicity in viral proteins involved in host entry 
through membrane fusion has recently been discussed in detail, and 
remains ‘an underutilized therapeutic target’26. 1EBOE.HELIX0 
(Table 2) also has a high hydrophobic moment, but is actually an 
isoleucine zipper derived from GCN427 (Figure 1b).
Helices with high proportion of negatively charged residues. 
Identifying difference among related species
We then analyzed the helices having a high proportion of nega-
tively charged residues, sorted based on the length of the helix 
when the percentage of negatively residues are the same (Table 2). 
Figure 2a shows the Edmundson wheel for the helix 4U2XA.
HELIX5 (which has only two charged residues - the basic E113 and 
D124), while Figure 2b,c shows this helix in the protein complex 
marked in magenta. Note, that we exclude AHs with either zero 
or one charged residues (see Methods). Protein PDBid:4U2XD is 
Table 3. Interactions obtained from the crystal 
structure of the Ebola virus glycoprotein in complex 
with a neutralizing antibody from a human survivor. 
The helix with a large hydrophobic moment, as 
determined from PDBid:1EBOE, is disrupted in the 
structure from PDBid:3CSY through possible hydrogen 
bonds with different residues in the human Fab KZ52 
heavy chain (antibody, chain A). The helix residues are: 
553-597 in chain J, PDBid:3CSY.
AtomEbola AtomAntibody Dist (Å)
ASP/552/OD1 
GLY/553/N 
ASN/550/O 
ASP/552/OD1 
ASN/550/ND2 
ASN/550/ND2 
ASP/552/OD2
SER/53/OG 
THR/100/OG1 
ASN/31/O 
SER/53/CB 
PRO/97/O 
ASN/31/O 
SER/53/OG
2.5 
2.7 
2.9 
2.9 
3.0 
3.2 
3.2
the human karyopherin alpha nuclear transporter (KPNA) C ter-
minus in complex with the Ebola virus VP24 protein (eVP24)18. 
eVP24 interferes with the immune response by selectively targeting 
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tyrosine-phosphorylated STAT1 nuclear import19. It does not hinder 
the transport of other cargo that may be required for viral replica-
tion. 4U2XA.HELIX5 is responsible for forming the complex with 
the KPNA protein through a helix (4U2XD.HELIX9, in blue), and 
K481 from KPNA is in contact with D124 from eVP24 (distance 
between K481/NZ and D124/OD2 is 3.98 Å). Their interaction is 
probably electrostatic, since the atoms have opposite charges. VP24 
has also been shown to directly bind to STAT1, further compromis-
ing the immune response28. Recently, KPNA was docked to Reston 
Ebola VP24 (PDBid:4D9OA)28 using the VP24 from Zaire Ebola 
(PDBid:4U2XA)18 as a template29. The docked structure showed 
that a single mutation might be one of the critical factors responsible 
for the non-pathogenic nature of Reston Ebola in humans30,31. Also, 
it was shown that the VP24 from Marburg virus (PDBid:3VNEA)28, 
which has a different immunosuppressive mechanism than the 
Ebola virus32, has different properties in the helices responsible for 
binding KPNA in the Zaire Ebola VP24.
The next helix having a high proportion of negatively charged 
residues (3FKEA.HELIX2) is from a VP35, a classic example of 
a moonlighting protein, that can be a component of the viral RNA 
polymerase complex, a viral assembly factor, or inhibitor of host 
interferon production33. This helix is part of the dsRNA-binding 
domain of VP35 that is involved in the formation of the asymmetric 
VP35 RBD dimeric interface in Reston Ebola virus through a hydro-
gen-bonding network of residues and a solvent molecule34. Interest-
ingly, this helix is homologous (100.0% similar and 78% identity in 
9 amino acid overlap) to helix ‘1A’ of an ATP-dependent transcrip-
tional activator35. This helix interacts with another ‘1B’ helix from a 
different monomer in an anti-parallel fashion to facilitate dimerization.
VP35 consists of several helices, and is reasonably conserved in 
the Marburg virus from the same Filoviridae family (42% iden-
tity, 58% similarity) (Figure 3a). Often, it is difficult to identify 
the regions of the protein that differ from a sequence or structural 
Figure 3. Polymerase cofactor VP35 (PDBid:3FKE). VP35 has several moonlighting functions related to immune evasion. (a) Sequence 
alignment of VP35 from Marburg (PDBid:4GHLA) and Ebola (PDBid:3FKEA). (b) Structural alignment using MUSTANG. The helices that 
have differing properties are marked in yellow. 3FKEA.HELIX1 spanning residues 238-252 is marked in magenta. This is a helix with a high 
proportion of positively charged residues that have been observed to have important interactions in the structure33. (c) Edmundson wheel for 
3FKEA.HELIX1. (d) 1D5 (in blue) in complex with VP35 (PDBid:4IBFA).
(a)
(a)
(c)(b)
(d)
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alignment (Figure 3b), in case there is interest in understanding dif-
ferent responses of the proteins to known drugs or even the immune 
system. Table 4 compares the characteristics of the helices in the 
VP35 from Ebola and Marburg (the helix numbering is offset by 
one, due to a small N-terminal helix in the Marburg protein (which 
might be due to crystallization technique differences and probably 
is not critical). Thus, we have numbered these helices using alpha-
bets. It can be seen that most of the helices have the same proper-
ties, barring helices E and F, where the acidic residue is present in 
the E helix in Marburg and in the F helix in Ebola. These helices 
are marked in yellow in Figure 3b. Also, it can be seen that helix 
C, which has a high proportion of acidic residues in VP35, has a 
fewer number of those residues in Marburg. The difference in the 
pathogenicity of these viruses are encoded in the structure of the 
expressed proteins, and the design of drugs and vaccines to counter 
virulence should take these differences into account.
Helices with high proportion of positively charged residues
4U2XA.HELIX7 from VP24 is a helix having a high proportion of 
positively charged residues (Table 2), and contains two (L147P and 
R154L) of three mutations (L147P, M71I and R154L) that sensi-
tizes guinea pigs to the Zaire Ebola virus36. This helix is marked in 
yellow in Figure 2c. The second helix (3FKEA.HELIX1) is from 
VP35, which was discussed previously33. This helix spans residues 
238-252 and includes Lys248 and Lys251, a basic patch which is 
‘100% identical among members of the Ebola viral isolates’33, and 
Ala238, Gln241, Leu242, Val245, Ile246, Leu249 which interacts 
with a β sheet to create a hydrophobic subdomain33. This helix 
is marked in magenta in Figure 3b, and the Edmundson wheel is 
Table 4. Detecting differences in related proteins based on 
characteristics of alpha helices. Comparing the VP35 protein from 
Marburg (PDBid:4GHLA) and Ebola (PDBid:3FKEA). Note the helices are 
offset by one, due the presence of an extra helix in the Marburg VP35. 
Thus, we name the helices using alphabets. It can be seen that most 
helices have the same properties, barring helices E and F, where the acidic 
residue is present in the E helix in Marburg and in the F helix in Ebola. HM: 
Hydrophobic moment, RPNR: Ratio of the positive to the negative residues, 
Len: length of the helix, NCH: number of charged residues.
Helix Name Real Helix Len HM RPNR NCH
A 4GHLA.HELIX1 3FKEA.HELIX0
10 
9
2.8 
5
0.5 
0.7
2 
3
B 4GHLA.HELIX2 3FKEA.HELIX1
15 
15
5.3 
7.8
1 
0.8
3 
4
C 4GHLA.HELIX3 3FKEA.HELIX2
13 
14
4.6 
3.2
0.5 
0.2
2 
4
D 4GHLA.HELIX4 3FKEA.HELIX3
11 
11
5.1 
3.6
1 
1
2 
2
E 4GHLA.HELIX5 3FKEA.HELIX4
3 
3
2.7 
1.1
0 
-1
1 
0
F 4GHLA.HELIX6 3FKEA.HELIX5
3 
3
1 
1.3
-1 
0.5
0 
2
G 4GHLA.HELIX7 3FKEA.HELIX6
6 
6
4.7 
4.7
1 
1
2 
2
H 4GHLA.HELIX8 3FKEA.HELIX7
3 
3
2.8 
3.4
0.5 
0.5
2 
2
shown in Figure 3c. Recently, antifiloviral compounds were shown 
to bind and inhibit the polymerase cofactor activity of VP3537. 
Figure 3d shows one of the compounds (1D5) in complex with 
VP35 (PDBid:4IBFA). It can be seen that atoms in the compounds 
make hydrogen bonds with residues on the AH spanning residues 
238–252 (Table 5). These structures were used to derive a receptor-
ligand pharmacophore, which was found to have similar features to 
the ligand based pharmacophore derived from four FDA approved 
drugs that inhibit the Ebola virus38. Once again, we demonstrate 
that unique values of an AH is a strong indicator of its significance 
in the viral functionality.
Multifunctional/moonlighting
The multifunctional roles played by many of these Ebola proteins is 
probably due to stretches of intrinsically disordered regions within the 
structure - ‘fuzzy objects with fuzzy structures and fuzzy functions’39. 
The conformational plasticity9 and moonlighting abilities of these 
proteins are key determinants for immune evasion40.
The above examples have analyzed all helices from the Ebola pro-
teome. However, it also possible to analyze the helices in a single 
protein, and probe those for unique features. Table 6 shows the val-
ues obtained from PAGAL for helices of the C-terminal domain of 
the Zaire Ebola virus nucleoprotein41. It can be seen that 4QAZA.
HELIX0 (residues 646-658) has a reasonably high hydrophobic 
moment (although it will not rank highly if we analyze all heli-
ces present in this proteome), and also a high number of charged 
residues (Figure 4a,b). It has been observed that ‘the side chains 
of Glu645, His646, Glu649, Lys684, Glu695, Glu709, Lys728 and 
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Figure 4. C-terminal domain of the Zaire Ebola virus nucleoprotein41. (a) Edmundson wheel for 4QAZA.HELIX0 (residues 646-658). (b) 
Protein structure for PDBid:4QAZA.
Table 5. VP35 (PDBid:4IBFA) in complex with a component 
(1D5) that inhibits its polymerase cofactor activity. Atoms 
making hydrophobic (HPhobic) and hydrogen bonds (HBond) 
with the inhibitor. The residues in the charged side of the 
Edmundson wheel in Figure 3c makes hydrogen bonds to 1D5.
VP35 atom 1D5 atom Dist (Å) Interaction type
LYS/251/NZ
GLN/241/NE2
ASP/302/O
LYS/251/CD
LYS/251/CE
GLN/244/OE1
ALA/221/CB
GLN/241/OE1
GLN/241/CD
GLN/244/NE2
OAD
OAB
CLA
OAD
OAD
CAM
OAA
OAB
OAB
OAB
2.6
2.7
3.0
3.2
3.3
3.3
3.5
3.5
3.5
3.5
HBond
HBond
HPhobic
HPhobic
HPhobic
HPhobic
HPhobic
HBond
HPhobic
HBond
Table 6. Properties of the helices of the C-terminal domain 
of the Zaire Ebola virus nucleoprotein (PDBid:4QAZA). 
4QAZA.HELIX0 comprising of residues 646-658 has a 
reasonably large hydrophobic moment, and has been 
hypothesized to be part of the protein which is involved in 
protein-protein interactions41. Further, these helices have 
residues with disordered sidechains41, which are known to be 
critical for moonlighting functions39. HM: Hydrophobic moment, 
RPNR: Ratio of the positive to the negative residues, Len: length 
of the helix, NCH: number of charged residues.
Helix Len HM RPNR NCH
4QAZA.HELIX0
4QAZA.HELIX1
4QAZA.HELIX2
4QAZA.HELIX3
4QAZA.HELIX4
4QAZA.HELIX5
4QAZA.HELIX6
13
12
3
3
4
3
11
8.4
0.8
2.5
2.4
1.8
0.1
2.1
0.7
0.7
0
0
0.3
-1
1
6
3
1
1
3
0
4
(a) (b)
Gln739 are partly disordered so that some or all of their atoms are 
not visible in the electron density’41. Glu645, His646, Glu649 are 
part of this helix, and are thus critical to the disorderedness of the 
protein, which is critical for its moonlighting roles. Note, that Glu 
has been observed to be the second most disorder promoting resi-
due (after proline)42. Furthermore, Tyr652 and Leu656, which lie in 
this helix, are residues that have been hypothesized to be part of the 
protein-protein interaction site involving this protein41.
Conclusions
The ability of a genome as small as the Ebola virus to inflict a dis-
hearteningly high percentage of mortality in human subjects is a 
humbling experience in the context of the tremendous technological 
advancements achieved in the last few decades3,4. The Ebola virus 
potently suppresses the human immune response2,6,43 by binding 
with key human proteins involved in the immune pathway18. These 
protein-protein interactions are often mediated through well struc-
tured secondary regions within the protein structures (alpha heli-
ces), and the design of molecules that inhibit these ‘hotspots’20,44 has 
been a well known strategy to develop drugs to counter bacterial 
and viral infections10–12. For example, synthetic peptides derived 
from the oligomerization domain of polymerase subunits has been 
shown to inhibit viral proteins45,46. In addition, there might exist 
other protein domains that might be exploited by non-native viral 
peptides to obstruct viral functionality. In the current work, we char-
acterize alpha helices in the Ebola virus proteome using a recently 
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implemented open access software (PAGAL)14, thus identifying 
potential targets for inhibition of the helix mediated interactions. 
Through several examples, we demonstrate that helices with unique 
features are involved in interactions with host proteins (either anti-
bodies from survivors, or proteins regulating the immune response). 
Further, we also provide an alternate way of analyzing differences 
in related proteins (from the Marburg virus) by focusing on the 
properties of corresponding helices. As future work, we intend to 
develop methodologies to design peptides that would target these 
‘hotspots’44. It has to be kept in mind that it has been a challenge to 
design small ligands that disrupt protein-protein interactions, and 
designers resort to several innovative techniques to overcome ther-
modynamic instability or proteolytic susceptibility47–50. These heli-
ces can essentially be epitopes51,52 for developing antibodies against 
the virus53,54. Interestingly, ZMapp, a cocktail of three antibodies 
has shown reversion of advanced Ebola symptoms in non-human 
primates55, and uses only glycoprotein-specific epitope generated 
antibodies52,56. It is interesting to hypothesize that additions to this 
cocktail with antibodies derived from other epitopes (for example, 
4U2XA.HELIX5 from VP24 that is involved in immune response 
suppression) could prove more effective. Thus, we provide a 
comprehensive list of potential targets within the small proteome of 
the Ebola virus that can directed rational design to quickly innovate 
therapies.
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target binding sites and for molecular modification studies e.g. site directed mutagenesis.
It would also have been useful to test other computational methods besides PAGAL or even describe the
pros/cons of these. Could they be used in consensus to improve predictions? Perhaps the authors can
comment on this.
I would clarify that our docking and pharmacophore computations (Ekins ref) only suggests FDAet al 
drugs chloroquine/ amodiaquine  may bind VP35. It is clear from the x-ray structures in the PDB that
several drug-like molecules can bind. We also have yet to verify our predictions but thank you for citing
this.
This study does make you wonder too what else could be done computationally for Ebola research, what
should be most helpful for drug discovery?
Probably a logical step might be to identify potential binding locations on the alpha helices for small
molecules and possibly dock compounds at these sites.
The authors clearly describe their approach and present results which can be tested by them or others in
future. With limited published scientific knowledge on the Ebola virus it is important that such
computational approaches are used.
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The authors have responded to my previous questions and improved the manuscript. Although, the
described computational approach can identify alpha helices with unique features, the author’s proposal
that the helical propensities can be linked to host protein interactions is rather weak and requires
experimental data to validate the method.
There are still a conceptual error in the manuscript:
Page 4: "The antibody most likely inhibits the rearrangement of GP2 segments, which abrogates the
."fusion of the internal loop in the host membrane
Do the authors mean that the antibody binding prevents Gp2 conformational changes required for
membrane fusion?
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`antibody binding prevents Gp2 conformational changes required for membrane fusion', which is
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The authors suggest that they can identify alpha helices and predict their propensities to be targeted by
small molecules. Their test case is the small Ebola virus genome, where several crystal structures are
available.
First they compute the hydrophobic moment of identified helices with their previously published program
PAGAL and classify them based on hydrophobicity, positive or negative charges. They conclude that
helices with unique feature values are involved in host protein interaction.
Page 4: It is not correct to state that “ this helix is disrupted by a neutralizing antibody derived from a
human survivor …”. HR1 or helix 1 from Gp2 is split into 4 small helices in the native GP structure and
antibody binding prevents its refolding into the post fusion conformation represented by the Gp2 structure.
Now one can argue that small molecules could interfere with the formation of the triple stranded coiled coil
formed by HR1 in the post fusion structure. This needs to be clarified in the text.
Next they identified a charged helix in Vps24 that interacts with karyopherin. Why was this chosen?
Because of the available structure? This helix contains only two charged residues and would not fall
under the classification of carrying a high charge!
The third helices described in detail are from Vps35 and the authors identify several helices with carry
charges, but no clear targets are discussed.
Page 6: The authors make a connection between the number of acidic residues in a helix from Ebola
Vps35 compared to Marburg Vps35 and the frequency of outbreaks, which is a complete over
interpretation of their data.
In summary the manuscript describes an interesting approach to identify or validate potential drug targets.
However, the authors need to be more cautious in interpreting their results. Without any experimental
validation their approach to link helical properties to protein interaction propensities is extremely weak.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed.Competing Interests:
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, Tata Institute of Fundamental Research, IndiaSandeep Chakraborty
Dear Dr Weissenhorn,
We would like to thank you for taking the time to review this paper, and for your suggestions to
improve the manuscript. In the interim period, we have applied other computational methods  to
correlate the different immunosuppressive and pathogenicity mechanisms in Ebola and Marburg
viruses to variations in their structures/sequences . Please find our detailed responses to your
comments below.
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The authors suggest that they can identify alpha helices and predict their propensities to
be targeted by small molecules. Their test case is the small Ebola virus genome, where
several crystal structures are available.
First they compute the hydrophobic moment of identified helices with their previously
published program PAGAL and classify them based on hydrophobicity, positive or
negative charges. They conclude that helices with unique feature values are involved in
host protein interaction.
Page 4: It is not correct to state that this helix is disrupted by a neutralizing anti- body
derived from a human survivor . HR1 or helix 1 from Gp2 is split into 4 small helices in the
native GP structure and antibody binding prevents its refolding into the post fusion
conformation represented by the Gp2 structure. Now one can argue that small molecules
could interfere with the formation of the triple stranded coiled coil formed by HR1 in the
post fusion structure. This needs to be clarified in the text.
We appreciate this point, (‘KZ52 likely neutralizes by preventing rearrangement of the GP2
’ ), andHR1A/HR1B segments and blocking host membrane insertion of the internal fusion loop
have made the correction.
Next they identified a charged helix in Vps24 that interacts with karyopherin. Why was this
chosen? Because of the available structure? This helix contains only two charged
residues and would not fall under the classification of carrying a high charge!
VP24 came up in the sorted list since it has a ‘high proportion of negatively charged residues’, and
not high charge. The proportion of charged residues is computed based on the total number of
charged residues, and not the length of the helix. We could also create a category of high charge
by combining the previous feature (high proportion) to high number of charged residues.
Our search criteria excludes AHs with zero or one charged residue. We had stated this in the
Methods section - We ignore the helices that have none or a single charged residue. We also had
a cutoff on the length of the AH as 10 - i.e. we are looking for reasonably long AHs - we had not
mentioned this constraint. We have modified the Methods section to reflect this. An AH having just
two similarly charged residues in a reasonably long AH (and none other) is relatively significant.
For example, one charged residue in VP24 (D124) makes an electrostatic contact with human
karyopherin, while the other one E113 makes a contact to Arg140 in another helix (α6) in VP24 .
The third helices described in detail are from Vps35 and the authors identify several
helices with carry charges, but no clear targets are discussed.
We have stated that ‘we have not been able to identify a critical role for this helix in the protein from
current literature’, which does not preclude the importance of these helices. This, in fact, highlights
the ability of our method to extract helices that might be of significance, yet not probed sufficiently
as targets. At the same time, it is also equally possible that this helix is not functionally significant.
Page 6: The authors make a connection between the number of acidic residues in ahelix
from Ebola Vps35 compared to Marburg Vps35 and the frequency of outbreaks, which is a
complete over interpretation of their data.
We agree with this criticism, and have made the corrections.
In summary the manuscript describes an interesting approach to identify or validate
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In summary the manuscript describes an interesting approach to identify or validate
potential drug targets.
We appreciate the positive and encouraging note on our efforts to use computational methods to
identify critical regions of interaction in the Ebola proteins, which could be easily extended to other
organisms as well.
However, the authors need to be more cautious in interpreting their results. Without any
experimental validation their approach to link helical properties to protein interaction
propensities is extremely weak.
We hope that we have addressed your concerns by the changes that we have made. We also
expect future results to corroborate some of our predictions, and will make the updates on the
f1000 site (which their format allows us to). We sincerely hope that the manuscript will be found
suitable in the modified form for publication.
Thanking you,
Sincerely,
Sandeep Chakraborty (Corresponding author)
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Further corroboration that characteristically distinct alpha helices are critical for interactions.
http://jvi.asm.org/content/early/2016/03/21/JVI.00322-16.full.pdf
"The loss of the alpha helix secondary structure at these epitopes between 1995 and 2004 is
intriguing and may warrant experimental data to understand its implications. Nonetheless, our
reconstructions support previous hypotheses that regions involved in critical interactions with
"the host proteins are often these unique alpha helices.
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